• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM ‐HF and ATMOSPHERE
ConclusionsIn HF, the impact of multimorbidity differed at the individual patient and population level, depending on the prevalence of and the risk related to each comorbidity, and the interaction between individual comorbidities. Patients with coexistent PAD and stroke were at greatest individual risk whereas, from a population perspective, coexistent CKD and hypertension mattered most.
Source: European Journal of Heart Failure - April 25, 2023 Category: Cardiology Authors: Pooja Dewan, Jo ão Pedro Ferreira, Jawad H. Butt, Mark C. Petrie, William T. Abraham, Akshay S. Desai, Kenneth Dickstein, Lars Køber, Milton Packer, Jean L. Rouleau, Simon Stewart, Karl Swedberg, Michael R. Zile, Scott D. Solomon, Pardeep Tags: Research Article Source Type: research

Impact of multimorbidity on mortality in HFrEF: Which comorbidities matter most? – An analysis of PARADIGM‐HF and ATMOSPHERE
ConclusionsIn HF, the impact of multimorbidity differed at the individual-patient and population level, depending on the prevalence of and the risk related to each comorbidity, and the interaction between individual comorbidities. Patients with co-existent PAD and stroke were at greatest individual risk whereas, from a population perspective, co-existent CKD and hypertension mattered mostThis article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - April 17, 2023 Category: Cardiology Authors: Pooja Dewan, Jo ão P Ferreira, Jawad H Butt, Mark C Petrie, William T Abraham, Akshay S. Desai, Kenneth Dickstein, Lars Køber, Milton Packer, Jean L Rouleau, Simon Stewart, Karl Swedberg, Michael R Zile, Scott D Solomon, Pardeep S Jhund, Tags: Research Article Source Type: research

Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy Original Research Articles
Conclusions Despite younger age, less comorbidity, and comprehensive use of conventional HF therapies, patients with Chagasic HF with reduced ejection fraction continue to have worse quality of life and higher hospitalization and mortality rates compared with other etiologies. Clinical Trial Registration PARADIGM-HF: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255; ATMOSPHERE: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00853658.
Source: Circulation: Heart Failure - November 15, 2017 Category: Cardiology Authors: Shen, L., Ramires, F., Martinez, F., Bodanese, L. C., Echeverria, L. E., Gomez, E. A., Abraham, W. T., Dickstein, K., Kober, L., Packer, M., Rouleau, J. L., Solomon, S. D., Swedberg, K., Zile, M. R., Jhund, P. S., Gimpelewicz, C. R., McMurray, J. J. V., o Tags: Heart Failure Original Research Articles Source Type: research

Two ‐Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non‐Interventional Prospective Study
The authors investigated the long‐term effectiveness and safety of aliskiren (ALIS) with particular attention on its association with dual blockade of the renin‐angiotensin system (RAS). The open, prospective 3A Registry (N=8723) in Germany assigned patients in a 4:1:1 ratio to ALIS, angiotensin‐converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), or non‐RAS drugs. Patients taking ALIS compared with those taking ACE inhibitors/ARBs or non‐RAS had more comorbidities and risk factors, were taking more antihypertensive agents, and had higher blood pressure (BP) values at entry. At 2 years, BP...
Source: The Journal of Clinical Hypertension - November 13, 2015 Category: Cardiology Authors: Uwe Zeymer, Ralf Dechend, Thomas Riemer, Evelin Deeg, Jochen Senges, David Pittrow, Roland Schmieder, Tags: Original Paper Source Type: research

Two‐Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non‐Interventional Prospective Study
The authors investigated the long‐term effectiveness and safety of aliskiren (ALIS) with particular attention on its association with dual blockade of the renin‐angiotensin system (RAS). The open, prospective 3A Registry (N=8723) in Germany assigned patients in a 4:1:1 ratio to ALIS, angiotensin‐converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), or non‐RAS drugs. Patients taking ALIS compared with those taking ACE inhibitors/ARBs or non‐RAS had more comorbidities and risk factors, were taking more antihypertensive agents, and had higher blood pressure (BP) values at entry. At 2 years, BP...
Source: The Journal of Clinical Hypertension - November 1, 2015 Category: Cardiology Authors: Uwe Zeymer, Ralf Dechend, Thomas Riemer, Evelin Deeg, Jochen Senges, David Pittrow, Roland Schmieder, Tags: Original Paper Source Type: research

Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS
Aliskiren previously was found to have potentially harmful effects in diabetic individuals prescribed concomitant angiotensin converting enzyme inhibitors (ACEI) or angiotenisn receptor antagonists (ARB). We explored potential effects of aliskiren on coronary atheroma progression and major adverse cardiovascular events (MACE: death/non-fatal MI/non-fatal stroke/hospitalization for heart failure/hospitalization for ACS/arterial revascularization) in patients with and without diabetes mellitus (DM).
Source: Atherosclerosis - October 21, 2015 Category: Cardiology Authors: Rishi Puri, Steven E. Nissen, Venu Menon, Mingyuan Shao, Amy Hsu, George L. Bakris, John J.P. Kastelein, Bryan Williams, Juergen Armbrecht, Patrick Brunel, Yu Kataoka, Stephen J. Nicholls Source Type: research

Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial
Conclusion The majority of deaths occurred in patients who did not experience a non-fatal CV or renal event, although the risk of death was higher following an event. Our findings illustrate continuing opportunities to reduce morbidity and mortality in patients with type 2 diabetes.
Source: European Heart Journal - September 21, 2015 Category: Cardiology Authors: Jhund, P. S., McMurray, J. J. V., Chaturvedi, N., Brunel, P., Desai, A. S., Finn, P. V., Haffner, S. M., Solomon, S. D., Weinrauch, L. A., Claggett, B. L., Pfeffer, M. A. Tags: Prevention and epidemiology Source Type: research

No Increase in Adverse Events During Aliskiren Use Among Ontario Patients Receiving Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers
Conclusions Among community-dwelling patients aged 66 years and older receiving therapy with an ACEi or an ARB, aliskiren use was not associated with hospitalization for hyperkalemia, AKI, or stroke.
Source: Canadian Journal of Cardiology - November 1, 2014 Category: Cardiology Source Type: research

Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial
Conclusions Sizeable reductions in BP, with potential for substantial CVD reduction, can be safely achieved using combinations of BP drugs in the elderly with normal high and Stage 1 hypertension. Clinical trial registration NCT01259297.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Teo, K. K., Pfeffer, M., Mancia, G., O'Donnell, M., Dagenais, G., Diaz, R., Dans, A., Liu, L., Bosch, J., Joseph, P., Copland, I., Jung, H., Pogue, J., Yusuf, S., on behalf of the Aliskiren Prevention of Later Life Outcomes trial Investigators Tags: Hypertension Source Type: research